secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orgenesis Inc. (—)
CIK:        0001460602
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001493152-25-013758
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orgenesis subsidiary enters $1M convertible loan; lender can convert to 80% equity, plus $10M facility
--------------------------------------------------------------------------------

- Initial loan $1M at 10% simple interest, 36-month maturity; after 30 days lender can convert to up to 80% of Orgenesis or Theracell equity.
- Lender receives warrant to purchase 15% fully diluted shares for $250,000, exercisable for 3 years.
- Credit facility up to $10M, with $7.1M already drawn; used to repay $6.1M in prior debt to Newtech and Ariel Malik.
- Lender may appoint three board members after 30 days, subject to regulatory approvals and shareholder meeting.
- If shareholder approval for share issuance not obtained within 60 days, lender gets option to acquire CellVira and Tissue Genesis assets at no cost.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1460602/000149315225013758/0001493152-25-013758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1460602/000149315225013758/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer